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Background and PurposezzIschemic lesion recurrence on diffusion-weighted imaging (DWI-
LR) is a frequently observed phenomenon after acute ischemic stroke. However, no study has elu-
cidated the impact of DWI-LR on functional outcome.
MethodszzAmong a consecutive series of patients who presented with focal symptoms or signs 
compatible with stroke within 48 hours from the onset over a 50-month period, those who had 
relevant ischemic lesions on initial DWI and underwent follow-up DWI within 14 days after the 
onset were enrolled in this study. As outcome variables, the scores on the modified Rankin Dis-
ability Scale (mRDS) at 3 months and 1 year were measured prospectively and dichotomized into 
good (0-2) vs. poor (3-6). When calculating odds ratios (ORs), adjustment was performed for 
age, previous stroke, initial score on the NIH Stroke Scale, stroke subtype, and IV thrombolysis.
ResultszzAmong those 786 patients finally enrolled in this study, 221 (28.1%) had DWI-LR. For 
a poor outcome at 3 months, the crude ORs of any, symptomatic, and asymptomatic DWI-LR 
were 2.70 [95% confidence interval (CI), 1.96 to 3.72], 10.03 (95% CI, 4.39 to 22.96), and 2.04 
(95% CI, 1.44 to 2.88), respectively. With adjustment, the OR of symptomatic DWI-LR was 6.44 
(95% CI, 2.50 to 16.57), whereas those of any and asymptomatic DWI-LR lost their statistical 
significance: 1.44 (95% CI, 0.94 to 2.20) and 1.04 (95% CI, 0.65 to 1.65), respectively. Analyzing 
with the 1-year outcome produced similar results.
ConclusionszzThis study shows that symptomatic early lesion recurrence can affect functional 
outcome after acute ischemic stroke, whereas an asymptomatic one may not.
  J Clin Neurol 2010;6:19-26
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Introduction
Ischemic lesion recurrence on diffusion-weighted imaging 
(DWI-LR) is a relatively common phenomenon in the acute 
stage of ischemic stroke, with an incidence of 30.4% within 
the first week
1 and about 40% at 1-3 months.
2-4 The risk of 
subsequent clinical events is more than threefold higher in 
patients with DWI-LR within 1 week after the index stroke 
than in those without DWI-LR.
4 Based on these results, DWI-
LR was proposed as a potential “surrogate endpoint”, which 
is defined as a measurement that can substitute for a true 
clinical endpoint in clinical trials.
4 However, criteria for valid 
surrogate endpoints require that the surrogate must be a cor-
relate of clinical outcome and fully capture the net effects of 
treatment on clinical outcome.
5
Early symptomatic recurrence after index stroke was re-
ported to aggravate the case fatality rate, disability, and prog-
nosis of stroke.
6-8 Although most cases of DWI-LR are clini-
cally silent, their pathogenesis is assumed to be identical to 
that of clinical recurrence of stroke.
3 The association of DWI-
LR with functional outcome may be similar to that of symp-
tomatic recurrence, although this remains to be proven. The 
aim of this study was to determine the impact of early DWI-
LR on functional outcome after acute ischemic stroke as mea-Early Ischemic Lesion Recurrence and Outcome
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This was a retrospective analysis of ischemic stroke and tran-
sient ischemic attack patients admitted to the stroke center of 
Seoul National University Bundang Hospital between Janu-
ary 2004 and February 2008. Based on the prospective stroke 
registry,
9 we selected patients 1) who presented with focal 
neurologic signs or symptoms compatible with stroke, 2) were 
hospitalized within 48 hours from the onset, and 3) had rele-
vant ischemic lesions on DWI. During the study period, a 
consecutive series of 1,364 patients were hospitalized due to 
stroke within 48 hours from the onset and had relevant isch-
emic lesions on initial DWI. Among them, 578 patients were 
excluded for the following reasons: 1) no follow-up DWI 
within 14 days after stroke onset (n=393), 2) not assessed for 
functional outcome on the mRDS at 3 months (n=20), or 3) 
having procedures that could cause ischemic lesions on fol-
low-up DWI iatrogenically (i.e., diagnostic cerebral angiog-
raphy, endovascular interventions of cerebral arteries, coro-
nary revascularization, heart surgery, and carotid endarterec-
tomy) (n=165).
10 A total of 786 patients were finally enrolled 
in this study. Most of the baseline characteristics did not dif-
fer significantly between those who were enrolled (n=786) 
and those who were excluded (n=578) (Table 1); excluded pa-
tients had more-severe neurologic deficits and a higher fre-
quency of cardioembolic stroke.
MRI protocols and diffusion-weighted imaging 
assessments
According to our stroke center’s protocol, all eligible patients 
with acute ischemic stroke were scheduled for an MRI scan 
at presentation and for a follow-up scan usually within 1 week 
of hospitalization. The median interval from initial DWI to 
the final follow-up DWI was 4 days (interquartile range, 2 to 
5 days). The MRI was conducted at 1.5 T (Intera, Philips Me-
dical Systems, Best, the Netherlands) with a sensitivity-encod-
ing head coil. DWI was performed using single-shot spin-
echo echo-planar imaging with the following parameters: 
matrix=128×128, slice thickness=5 mm, TR=4,000-5,000 ms, 
TE=56-65 ms, and b=1,000 s/mm
2.
All MRI scans that were performed within 14 days from 
stroke onset were reviewed by two neurologists (WJ Kim 
and Y Ko). DWI-LR was judged by them independently and 
blind to clinical information (kappa=0.83). Discrepancies were 
Table 1. Comparison of baseline characteristics between enrolled and excluded subjects
Characteristic Enrolled (n=786) Excluded (n=578) p value*
Sex, male  475 (60.4) 347 (60.0) 0.88
Age, years, mean±SD 67.4±12.1 66.5±12.9 0.21
Hypertension 463 (58.9) 350 (60.6) 0.54
Diabetes 235 (29.9) 158 (27.3) 0.30
Hyperlipidemia 133 (16.9) 089 (15.4) 0.45
Atrial fibrillation 102 (13.0) 097 (16.8) 0.05
Previous TIA 47 (6.0) 38 (6.6) 0.65
Previous stroke 155 (19.7) 129(22.3) 0.24
Smoking
† 225 (28.6) 173 (29.9) 0.60
FBS (mg/dL), mean±SD 148.4±64.7 148.2±70.4 0.75
SBP (mmHg), mean±SD 161.9±28.5 159.7±27.9 0.17
DBP (mmHg), mean±SD 086.7±17.1 086.7±16.5 0.95
Score on NIHSS, median (IQR)  4 (2-7) 4.5 (2-11) 0.01
IV thrombolysis 52 (6.6) 35 (6.1) 0.68
TOAST classification <0.01
Small-artery occlusion 200 (25.4) 087 (15.1)
Large-artery atherosclerosis 295 (37.5) 223 (38.6)
Cardioembolism 152 (19.3) 137 (47.4)
Other determined cause 08 (1.0) 19 (3.3)
Undetermined cause 131 (16.7) 112 (19.4)
Values are number of patients (%) except where indicated. 
*p values were calculated by Pearson’s chi-square test, Student’s t-test, or Mann-Whitney U test, †Current smoker or ceased smoking 
within 5 years prior to admission.
SD: standard deviation, TIA: transient ischemic attack, FBS: fasting blood sugar, SBP: systolic blood pressure, DBP: diastolic blood pres-
sure, IQR: interquartile range, NIHSS: NIH Stroke Scale, TOAST: Trial of Org 10172 in Acute Stroke Treatment. Kim WJ et al.
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resolved by consensus. DWI-LR was defined as the presence 
of a newly developed ischemic lesion on follow-up DWI 
outside the region of the acutely symptomatic (index) lesions.
1 
Enlargement of the initial ischemic lesion was not regarded 
as a new ischemic lesion.
1 New lesions were determined by 
slice-to-slice comparison of DWI scans across time points.
Clinical assessment
Clinical data were obtained from the stroke registry
9 primari-
ly and with additional review of the medical records if nec-
essary. Among those lesions satisfying the MRI-based defini-
tion of DWI-LR, symptomatic DWI-LR was identified as the 
presence of newly developed neurological deficits that were 
clearly different from those of the index stroke.
11 Lesions due 
to systemic causes of clinical deterioration (e.g., hypoxia, 
hypotension, hypo- or hyperglycemia, or infection) were not 
considered symptomatic. New lesions compatible with the 
MRI-based definition of DWI-LR but not identified as symp-
tomatic were designated as asymptomatic DWI-LR. All pa-
tients were on antiplatelets or anticoagulants to prevent stroke 
recurrence, and also received treatment with other measures 
appropriate for secondary prevention of stroke (e.g., statins, an-
tihypertensives, and hypoglycemics) based on current stroke 
guidelines.
12,13
Stroke subtypes were categorized according to the classifi-
cation of the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST):14 1) large-artery atherosclerosis, 2) cardioembo-
lism, 3) small-artery occlusion, 4) stroke of other determined 
cause, or 5) stroke of undetermined cause. We modified the 
criterion for lesion size of small-vessel occlusion to be less 
than 20 mm based on a report that an acute ischemic lesion 
is generally larger in DWI than in CT or conventional MRI.
15
At 3 months and 1 year after stroke onset, the functional 
status of each patient was determined through telephone in-
terview by a trained nurse (MH Yang) using the mRDS
16 as 
part of a program monitoring the quality of inpatient stroke 
care. The mRDS score ranges from 0 to 6, with higher scores 
indicating greater disability (6 indicates death). For the anal-
ysis, the mRDS score was dichotomized into “good out-
come” (0 to 2; patient is independent) vs. “poor outcome” (3 
to 6; patient is dependent or dead).
17
Power calculation
Before acquiring imaging data and refining the clinical data 
set by reviewing medical records, the power of this study was 
calculated based on the following assumptions. First, the fre-
quency of DWI-LR was assumed to be 34% based on a pre-
vious report.
1 Second, poor outcome was estimated as 30% 
in the no-DWI-LR group, based on 33.7% of those in the origi-
nal cohort having a poor outcome (mRDS score ≥3); note 
that information on the mRDS score was available for 1,512 
of 1,602 patients at 3 months. Third, the postulated odds ra-
tio (OR) values were 1.5, 2.0, and 3.0, which for the final 786 
subjects gave calculated powers of 72%, 99%, and 99%, re-
spectively. All calculations were performed using nQuery 
Advisor (version 6.1, Statistical Solutions, Cork, Ireland). 
Statistical analyses 
Continuous variables are expressed as mean±standard devia-
tion or median (interquartile range) values, whereas categor-
ical variables are presented as absolute values and percent-
ages. We compared baseline characteristics according to the 
presence of DWI-LR. Student’s t-test or the Mann-Whitney 
U test was used for continuous variables, and Pearson’s chi-
square test was used for categorical variables. To express the 
association of any, symptomatic, and asymptomatic DWI-
LR with functional outcome, ORs and their 95% confidence 
intervals (CIs) were calculated using logistic regression with 
and without adjustment. Variables were selected for adjust-
ment if 1) they showed p<0.2 in bivariate analyses with both 
functional outcome and DWI-LR, and 2) they were judged 
to be clinical relevant.
In order to check whether dichotomizing a polychotomous 
outcome variable influences the analysis results, we performed 
repeated logistic analysis with two other dichotomizations: 
mRDS scores of 0/1 vs. 2-6 and 0-3 vs. 4-6.
Statistical analyses were performed using SPSS 15.0 for 
Windows (SPSS, Chicago, IL, USA) and a probability value 
of p<0.05 was considered statistically significant.
Results
Among 786 patients who were finally enrolled in this study, 
221 (28.1%) had any DWI-LR, with 180 (22.9%) having as-
ymptomatic DWI-LR and 41 (5.2%) having symptomatic 
DWI-LR. Those in the DWI-LR group were older, had a 
higher prevalence of atrial fibrillation, presented with lower 
systolic blood pressure, lower diastolic blood pressure, and 
higher initial score on the NIH Stroke Scale (NIHSS), and 
received IV thrombolysis more frequently than those in the 
no-DWI-LR group (Table 2). DWI-LR occurred only rarely 
in those with small-artery occlusion (4.1%). Previous stroke 
tended to be more common in the DWI-LR group. With ad-
ditional consideration of clinical relevance and the correla-
tion with functional outcome, age, initial score on the NI-
HSS, TOAST classification, IV thrombolysis, and previous 
stroke were chosen as variables for adjustment.
The functional outcome was worse in the DWI-LR group 
than in the no-DWI-LR group (Table 3). At 3 months the out-
come was poor (mRDS score of 3-6) in 28.7% and 52.0% of Early Ischemic Lesion Recurrence and Outcome
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subjects in the no-DWI-LR and DWI-LR groups, respective-
ly, and the ORs of any DWI-LR before and after adjustment 
were 2.70 (95% CI, 1.96 to 3.72) and 1.44 (95% CI, 0.94 to 
2.20), respectively (Table 4). We analyzed the association be-
tween asymptomatic DWI-LR and functional outcome by re-
moving 41 symptomatic recurrent stroke patients from the 
data set. On crude analysis the contribution of asymptomatic 
DWI-LR to functional outcome remained significant (Table 
4), but the significance disappeared after adjustment (adjust-
ed OR, 1.04; 95% CI, 0.63 to 1.61). Symptomatic DWI-LR 
was associated with poor outcome (adjusted OR, 6.44; 95% 
CI, 2.50 to 16.57).
The results were not changed in additional analyses with 
1-year outcome or stratification by TOAST (Table 3 and 4). 
Repeated analyses with different dichotomization methods for 
outcome variable (mRDS scores of 0/1 vs. 2-6 and 0-3 vs. 
Table 3. Functional outcome (mRDS score) at 3 months and 1 year by DWI-LR
Modified Rankin Disability Scale
0 1 2 3 4 5 6
At 3 months
   No DWI-LR (n=565) 189 (33.5) 124 (21.9) 90 (15.9) 93 (16.5) 36 (6.4)0 19 (3.4)0 14 (2.5)0
   Any DWI-LR (n=221)
Asym LR (n=180) 048 (26.7) 024 (13.3) 27 (15) 29 (16.1) 18 (10) 25 (13.9) 9 (5)
Sym LR (n=41) 01 (2.4) 03 (7.3) 3 (7.3) 06 (14.6) 8 (19.5) 14 (34.1) 6 (14.6)
At 1 year 
   No DWI-LR (n=428) 189 (44.2) 058 (13.6) 62 (14.5) 59 (13.8) 22 (5.1) 16 (3.7)0 22 (5.1)0
   Any DWI-LR (n=178) 
Asym LR (n=146) 051 (34.9) 11 (7.5) 19 (13) 20 (13.7) 10 (6.8) 14 (9.6)0 21 (14.4)
Sym LR (n=32) 02 (6.3) 03 (9.4) 1 (3.1) 04 (12.5) 4 (12.5) 5 (15.6) 13 (40.6)
Values are number of patients (%).
Asym LR: asymptomatic DWI-LR, Sym LR: symptomatic DWI-LR, mRDS: modified Rankin disability scale, DWI-LR: lesion recurrence on 
diffusion-weighted imaging.
Table 2. Baseline characteristics by the presence of ischemic lesion recurrence on diffusion-weighted MRI (DWI) (DWI-LR)
 No DWI-LR (n=565, 71.9%) DWI-LR (n=221, 28.1%) p value*
Male sex 334 (59.1) 141 (63.8) 0.230
Age (years), mean±SD 066.5±11.9 069.6±12.1 0.001
Hypertension 338 (59.8) 125 (56.6) 0.400
Diabetes 174 (30.8) 061 (27.6) 0.380
Hyperlipidemia 102 (18.1) 031 (14.0) 0.180
Atrial fibrillation 45 (8.0) 057 (25.8) <0.010
Previous TIA 33 (5.8) 14 (6.3) 0.790
Previous stroke 102 (18.1) 053 (24.0) 0.060
Smoking 169 (29.9) 056 (25.3) 0.200
FBS (mg/dL), mean±SD 150.4±66.4 143.8±61.6 0.200
SBP (mmHg), mean±SD 163.4±27.6 157.9±30.4 0.020
DBP (mmHg), mean±SD 088.1±16.7 083.3±17.8 0.001
Score on NIHSS, median (IQR)  04 (2-5) 006 (3-11) <0.010
IV thrombolysis 23 (4.1) 029 (13.1) <0.010
FAT to F/U DWI time (days), median (IQR) 04 (2-5) 03 (2-5) 0.550
TOAST classification <0.010
Small-artery occlusion 191 (33.8) 09 (4.1)
Large-artery atherosclerosis 199 (35.2) 096 (43.4)
Cardioembolism 081 (14.3) 071 (32.1) 
Other determined cause 05 (0.9) 03 (1.4)
Undetermined cause 089 (15.8) 042 (19.0)
*p values are calculated by Mann-Whithey U test, Student’s t-test, or Pearson’s chi-square test if appropriate.
SD: standard deviation, TIA: transient ischemic attack, FBS: fasting blood sugar, SBP: systolic blood pressure, DBP: diastolic blood pres-
sure, IQR: interquartile range, NIHSS: NIH Stroke Scale, FAT: first abnormal time, F/U: follow-up, TOAST: Trial of Org 10172 in Acute Stroke 
Treatment. Kim WJ et al.
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4-6) also did not show a significant association between as-
ymptomatic DWI-LR and functional outcome after adjust-
ment (results are not presented here).
Discussion
To the best of our knowledge, this is the first study of the im-
pact of early asymptomatic ischemic lesion recurrence on 
functional outcome of acute ischemic stroke. There are pre-
vious reports on the clinical importance of early lesion recur-
rence with respect to predicting late lesion recurrence
3 and 
subsequent clinical events,
4 and even lesion recurrence has 
been suggested as a surrogate endpoint of stroke prevention 
trials.
1,3,4,18 However, the present study shows that asymptom-
atic ischemic lesion recurrence may not influence clinical out-
come at 3 months, at least in terms of functional disability. 
Several reasons can be suggested for the absence of an as-
sociation between DWI-LR and mRDS at 3 months. An effect 
of asymptomatic DWI-LR on outcome could be mediated 
via an increased risk of further clinical events, or directly by 
the effect of silent ischemic lesions themselves. With respect 
to subsequent clinical events, 3 months of observation might 
have been too short for subsequent clinical events to occur and 
aggravate the clinical outcome in the DWI-LR group. In a 
previous study, recurrent ischemic stroke occurred in 11.4% 
of subjects in the early silent lesion recurrence group and in 
Table 4. Odds ratios (ORs) for disability at 3 months and 1 year
 Crude OR (95% CI) Adjusted OR (95% CI)
At 3 months
    Any DWI-LR (n=786) 02.70 (1.96-3.72) 01.44 (0.94-2.20)*
SAO 00.60 (0.072-4.9) 00.88 (0.082-9.383)†
LAA 02.09 (1.27-3.42) 1.149 (0.619-2.134)†
CE 02.44 (1.25-4.73) 1.621 (0.663-3.960)†
        Previous stroke 02.78 (1.94-3.98) 02.23 (1.45-3.44)*
        Initial score on NIHSS 01.33 (1.26-1.39) 01.32 (1.25-1.40)*
        IV thrombolysis  01.50 (0.85-2.65) 00.44 (0.21-0.95)*
        Age 01.06 (1.04-1.07) 01.05 (1.03-1.07)*
    TOAST classification
SAO 1 1
LAA 04.35 (2.82-6.72) 02.42 (1.47-3.99)
CE 03.36 (2.06-5.49) 01.07 (0.58-2.01)
OC+UC 02.11 (1.26-3.55) 01.34 (0.73-2.48)
    Asymptomatic LR (n=745) 02.04 (1.44-2.88) 01.04 (0.63-1.61)*
SAO 00.60 (0.07-4.95) 0.880 (0.082-9.383)†
LAA 01.55 (0.90-2.66) 0.681 (0.329-1.409)†
CE 01.97 (0.99-3.91) 1.255 (0.492-3.203)†
    Symptomatic LR (n=786) 10.03 (4.39-22.96) 06.44 (2.50-16.57)*
At 1 year
    Any DWI-LR (n=606) 02.72 (1.89-3.90) 01.33 (0.81-2.17)*
        Previous stroke 03.04 (2.04-4.54) 02.50 (1.53-4.07)
Initial score on NIHSS 01.32 (1.25-1.40) 01.33 (1.24-1.41)*
IV thrombolysis 01.63 (0.88-3.03) 00.41 (0.18-0.95)*
Age 01.07 (1.05-1.08) 01.06 (1.04-1.08)*
TOAST classification
SAO 1 1
LAA 04.22 (2.58-6.90) 02.31 (1.29-4.12)
CE 04.05 (2.20-7.12) 01.27 (0.62-2.60)
OC+UC 01.81 (0.99-3.33) 01.24 (0.60-2.26)
    Asymptomatic LR (n=574) 02.08 (1.41-3.07) 00.92 (0.53-1.59)*
    Symptomatic LR (n=606) 09.18 (3.72-22.70) 06.90 (2.30-20.64)*
*Adjusted for previous stroke, initial score on NIHSS, IV thrombolysis, age, and TOAST classification, †Adjusted for previous stroke, initial 
score on NIHSS, IV thrombolysis, and age. 
DWI-LR: lesion recurrence on diffusion-weighted imaging, SAO: small-artery occlusion, LAA: large-artery atherosclerosis, CE: cardio-
embolism, NIHSS: NIH Stroke Scale, OC: other determined cause, UC: undetermined cause.Early Ischemic Lesion Recurrence and Outcome
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5.8% of the no-recurrence group during a follow-up of 19.3 
±9.0 months.
4 The higher proportion of subjects with small-
artery occlusion in the present study compared to that study 
(25.4% vs. 17.4%) may be another reason. An effect of silent 
ischemic lesions on outcome may be too small to be detected 
by applying the mRDS to a sample of this size. The mRDS 
has been widely used for measuring functional disability af-
ter stroke. Whilst its validity and reliability have been confirm-
ed,
16,19 it might be not sufficiently sensitive to detect small 
differences. Neuropsychological deficits in the absence of 
clinical stroke after coronary bypass surgery
20,21 and cogni-
tive deficits associated with new infarcts on MRI, mostly as-
ymptomatic, in an elderly cohort
22 suggest that more-sophis-
ticated methods-such as cognitive tests or measures of the 
quality of life-could reveal the impact of silent lesions on func-
tional outcome. Furthermore, even when using the mRDS, 
increasing the sample size may only enable the detection of a 
modest contribution of DWI-LR to functional outcome, such 
as an OR of 1.5 or less. Further studies with larger samples 
and appropriate tools are warranted. 
Lesion growth and lesion recurrence can be considered to 
be two major types of changes in ischemic lesions on DWI-
MRI causing neurological deterioration after acute ischemic 
stroke. Evolution of ischemic lesions is very common,
23 and 
ischemic lesion growth is strongly correlated with clinical out-
come.
24,25 Therefore, the negative correlation between asymp-
tomatic lesion recurrence and clinical outcome can be explain-
ed by the impact on clinical outcome being greater for lesion 
growth than for lesion recurrence. However, lesion growth was 
not measured in this study.
The frequency of DWI-LR in this study was 28.1% and var-
ied according to TOAST classification, from 46.7% in cardio-
embolic stroke to 4.5% in lacunar stroke. The reported inci-
dence of early lesion recurrence has varied from 33.7% to 
34.3%.
1,3,4 The lower frequency of DWI-LR in our study may 
be attributable to the proportion of subjects with small-artery 
occlusion being higher in our study than in previous studies 
(25.4% vs. 12.1% and 12.5%).
1,4 
The rate of symptomatic DWI-LR was 5.2% in this study. 
Considering that we used all DWI scans that were performed 
within 14 days from symptom onset, this rate is similar to those 
of previous studies: the reported cumulative rates of clinical 
stroke recurrence were 2% within 1 week
26 and 1.6-8% with-
in 2 weeks.
27-29 As expected, this study showed that symptom-
atic DWI-LR was strongly correlated with poor outcome in 
terms of functional disability at 3 months after stroke (crude 
and adjusted ORs, 10.03 and 6.44, respectively), which is 
similar to previous studies of the impact of early recurrence of 
stroke on functional disability.
7,30,31 
Specific evidence is necessary for a surrogate endpoint to 
be considered an adequate substitute for the real endpoint. A 
surrogate endpoint has biologic relevance in terms of 1) the 
relationship between the candidate surrogate and true outcome, 
2) synchronized changes among the surrogate endpoint and 
functional status, 3) reflection of the pathophysiologic pro-
cess, and 4) the association between the surrogate endpoint 
and true outcome.
5 Because the present study showed that 
early asymptomatic ischemic lesion recurrence does not pre-
dict functional disability after stroke, DWI-LR is not an ap-
propriate surrogate marker for use in clinical trials aimed at 
improving functional disability caused by stroke. Instead, isc-
hemic lesion growth may be more helpful than lesion recur-
rence.
This study was subject to some limitations. First, this was a 
single-center, retrospective cohort study. Second, we excluded 
40% of patients hospitalized during the study period. Although 
most baseline characteristics were comparable, the subjects 
who were excluded had more-severe neurological deficits, 
less-frequent small-artery occlusion, and more-frequent cardio-
embolic stroke. Third, follow-up DWI was performed at var-
ious intervals from stroke onset, although the interval did not 
differ between the DWI-LR-positive and DWI-LR-negative 
groups. 
In conclusion, this study shows that symptomatic early le-
sion recurrence can affect functional outcome after acute isch-
emic stroke, whereas asymptomatic early lesion recurrence 
may not. However, the use of more sophisticated tools for de-
tecting subtle changes due to asymptomatic recurrence with 
larger samples may produce different results. 
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Supplement table. Comparison of baseline characteristics by functional outcome at 3 months (n=786)
Variables Good outcome (n=509) Poor outcome (n=277) p value
Sex (male) 323 (63.5) 152 (54.9) 0.02
Age (years), mean±SD  064.9±11.7 0072.1±11.2 <0.01
Hypertension  297 (58.3) 166 (59.9) 0.67
Diabetes 151 (29.7) 084 (30.3) 0.85
Hyperlipidemia 091 (17.9) 042 (15.2) 0.33
Atrial fibrillation  053 (10.4) 049 (17.7) 0.01
Previous TIA 26 (5.1) 21 (7.6) 0.16
Previous stroke 070 (13.8) 085 (30.7) <0.01
Smoking  164 (32.2) 061 (22.2) 0.01
FBS (mg/dL), mean±SD 148.6±64.6 148.1±64.9 0.99
SBP (mmHg), mean±SD 161.2±28.5 163.1±28.5 0.36
DBP (mmHg), mean±SD 087.3±17.4 085.8±16.4 0.23
Score on NIHSS, median (IQR) 03 (2-5) 007 (4-12) <0.01
IV thrombolysis 29 (5.7) 23 (8.3) 0.16
FAT to F/U DWI time (days), median (IQR) 04 (3-5) 03 (2-5) 0.53
TOAST classification <0.01
Small artery occlusion 166 (32.6) 034 (12.3)
Large artery atherosclerosis 156 (30.6) 139 (50.2)
Cardioembolism 090 (17.7) 062 (22.4)
Other determined cause 06 (1.2) 02 (0.7)
Undetermined cause 091 (17.9) 040 (14.4)
Values are number of patients (%) except where indicated. 
*p values were calculated by Pearson’s chi-square test, Student t-test or Mann-Whitney U Test. 
FBS: fasting blood sugar, SBP: systolic blood pressure, DBP: diastolic blood pressure, NIHSS: NIH Stroke Scale, IQR: interquartile range, 
DWI: diffusion-weighted imaging, TOAST: Trial of Org 10172 in Acute Stroke Treatment.
Supplement